Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies

NCT07635511 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Hematological Malignancies
Platelet Transfusion Refractoriness (PTR)
HLA Antibodies

Interventions

DRUG: Acalabrutinib maleate
DRUG: bortezomib
OTHER: HLA-matched or crossmatched irradiated platelets
DRUG: human immune globulin

Sponsor

The First Affiliated Hospital of Soochow University